Estradiol-Receptor Blockade in Older Men and Women
Completed · Phase 1 · Has a placebo group
Conditions studied: Normal Healthy Volunteers
In brief
Repletion of testosterone (Te) in older men drives GH secretion after its aromatization to estradiol (E2), which acts via the estrogen receptor (ER). Conversely, we postulate that estrogen deprivation in postmenopausal women attenuates growth hormone (GH) secretion and insulin-like growth factor-1 (IGF-I) production, thus favoring development of metabolic syndrome in men treated with toremifene, a new estrogen antagonist used adjunctively in prostatic cancer
Key facts
- Study ID
- NCT02271282
- Run by
- Mayo Clinic
- People needed
- 40
- Starts
- 2014-12-01
- Expected to finish
- 2016-05-01
- Last updated by the study team
- 2016-09-14
Who can join
Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.